BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 248 filers reported holding BLUEPRINT MEDICINES CORP in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $542,075 | -21.6% | 10,794 | -1.3% | 0.00% | – |
| Q2 2023 | $691,155 | +43.8% | 10,936 | +2.4% | 0.00% | – |
| Q1 2023 | $480,471 | +28.2% | 10,680 | +24.8% | 0.00% | – |
| Q4 2022 | $374,816 | +19.7% | 8,556 | +80.3% | 0.00% | – |
| Q3 2022 | $313,000 | +24.7% | 4,746 | +102.2% | 0.00% | – |
| Q4 2021 | $251,000 | +5.0% | 2,347 | +0.8% | 0.00% | – |
| Q3 2021 | $239,000 | -86.9% | 2,328 | -87.6% | 0.00% | -100.0% |
| Q1 2021 | $1,829,000 | +482.5% | 18,809 | +571.0% | 0.00% | – |
| Q4 2020 | $314,000 | 0.0% | 2,803 | -17.2% | 0.00% | – |
| Q3 2020 | $314,000 | +37.7% | 3,384 | +15.6% | 0.00% | – |
| Q2 2020 | $228,000 | -17.1% | 2,928 | -14.6% | 0.00% | -100.0% |
| Q4 2019 | $275,000 | +16.5% | 3,428 | +6.9% | 0.00% | – |
| Q3 2019 | $236,000 | -74.5% | 3,207 | -67.3% | 0.00% | -100.0% |
| Q2 2019 | $925,000 | +201.3% | 9,810 | +156.1% | 0.00% | +100.0% |
| Q1 2019 | $307,000 | -25.3% | 3,830 | -27.2% | 0.00% | 0.0% |
| Q3 2018 | $411,000 | – | 5,262 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 705,159 | $12,728,000 | 12.46% |
| BVF INC/IL | 2,640,251 | $47,657,000 | 11.79% |
| Casdin Capital, LLC | 321,300 | $5,799,000 | 6.66% |
| Opaleye Management Inc. | 220,000 | $3,971,000 | 2.48% |
| PFM Health Sciences, LP | 1,420,511 | $25,640,000 | 0.79% |
| Perceptive Advisors | 404,404 | $7,299,000 | 0.64% |
| Partner Investment Management, L.P. | 18,788 | $339,000 | 0.55% |
| Visium Asset Management, LP | 1,265,025 | $22,834,000 | 0.39% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 661,717 | $11,944,000 | 0.39% |
| Virtus ETF Advisers LLC | 10,484 | $189,000 | 0.26% |